title: Alternative therapeutic strategies for patients with severe end-stage coronary artery disease not amenable to conventional revascularization.
abstract: Although there have been remarkable advances in medical therapy, percutaneous coronary interventions, and coronary artery bypass graft surgery, complete revascularization remains a challenge given the more complex coronary artery disease prevalent in contemporary practice. The lack of donors for cardiac transplantation will fuel the search for effective alternative strategies for dealing with patients with severe ischemic heart disease not amenable to conventional revascularization techniques. Percutaneous laser revascularization clearly diminishes anginal symptoms; however, the blinded trials have provided conflicting results, with one study showing a definite decrease in angina and another suggesting that the placebo effect may play a major role in this modality. Similarly, surgical transmyocardial laser revascularization is limited by the lack of consistent improvement in objective measurements of ischemia and the potential confounding mechanisms of denervation and the placebo effect, and thus should be reserved for only the most highly selected patients. Although enhanced external counterpulsation is associated with an improvement in anginal symptoms and exercise tolerance, this modality is limited by its availability, tolerability, and rigid exclusion criteria. Of the alternative strategies available, therapeutic angiogenesis holds the most promise. However, the long-term results of ongoing randomized clinical trials require further scrutiny. Novel methods for vascular reconstruction are evolving techniques, but should be viewed currently as mainly experimental methods. The common goals of these new treatment options would be to reduce symptoms, decrease morbidity, and potentially improve mortality by reducing ischemia through favorably impacting myocardial oxygen supply and demand. The optimal management of patients with severe end-stage coronary artery disease not amenable to conventional revascularization techniques will continue to remain a challenge for the clinician and will be the main focus of basic cardiovascular research and clinical trials in the new millennium.
authors.affiliation: Rush Heart Institute, Rush-Presbyterian-St. Luke's Medical Center and Rush Medical College, Chicago, Illinois 60612, USA.
authors.forename: Francis Q
authors.initials: FQ
authors.lastname: Almeda
authors.forename: Joseph E
authors.initials: JE
authors.lastname: Parrillo
authors.forename: Lloyd W
authors.initials: LW
authors.lastname: Klein
mesh_terms: D016342:Angioplasty, Laser; D000818:Animals; D000529:Complementary Therapies; D003324:Coronary Artery Disease / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D009204:Myocardial Revascularization; D009206:Myocardium / Q000473:pathology; D012307:Risk Factors; D012720:Severity of Illness Index